A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection | MicrobiomeTrials← Back to trialsNCT07694557
A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-29Est. Completion: 2028-07-01
Enrollment target: 180 participants Locations- Anning First People's Hospital, Anning, Yunnan, China
Other microbiome trials you might be interested in
Respiratory Syncytial Virus InfectionsImmunocompromised HostInfluenzaCOVID - 19
Respiratory syncytial virus (RSV), influenza, and SARS-CoV-2 are common respiratory viruses. In healthy adults they usua…
Multiple LocationsEst. completion Dec 31, 2025
ImmunityRespiratory InfectionAsthma
This prospective observational study will enroll approximately 1,200 children from birth through 7 years of age in Zheji…
Dongyang, ChinaEst. completion Dec 31, 2036